# A Study of Lasmiditan in Healthy Volunteers

> **NCT04749914** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 97 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lasmiditan
- **DRUG:** Dabigatran Etexilate
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT04749914
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2021-07-06
- **Final completion:** 2021-07-06
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04749914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04749914, "A Study of Lasmiditan in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04749914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*